Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (780)	12/28/1999 10:53:00 PM
From: tommysdad	Read Replies (3) \| Respond to of 3158

DAK, Of the companies you've listed, I only follow NBIX and ABSC and both companies have shareholder rights plans. <<Also, if MEDI had bid $6 for BTRN when it was trading @ $3, wouldn't the shareholders decide weather to sell >> The normal course of events would be for the acquiring company to discuss a buyout with the management of the "buy-ee", not to bid for the company on the open market. Without management approval, such a buyout would be difficult for most of these companies. I didn't follow all of the biotech buyouts this year, but I am not aware of a hostile buyout of a biotech. Look at the MRK buyout of SIBI -- even with a buyout at a 110% to market, a bunch of shareholders were quite upset and at least one lawsuit was filed. So, no, I think if someone had attempted a hostile takeover of BTRN at a 100% premium to market, they would have failed. Most people do not buy biotechs for a double -- the risk/reward ratio isn't right. Can you imagine what the current market price of SIBI, AGPH, or SUGN would be in the current biotech market? I do -- I owned them all. But the new Excursion will have to wait, because MRK, WLA, and PNU haven't done diddly. (OK, MRK gave cash, but you get the idea). I wasn't happy with the buyouts, though at the time I understood the managements' positions. TD